CH622020A5 - - Google Patents
Download PDFInfo
- Publication number
- CH622020A5 CH622020A5 CH153980A CH153980A CH622020A5 CH 622020 A5 CH622020 A5 CH 622020A5 CH 153980 A CH153980 A CH 153980A CH 153980 A CH153980 A CH 153980A CH 622020 A5 CH622020 A5 CH 622020A5
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- hydrogen
- trihydroxy
- oxa
- trans
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 description 13
- 150000004702 methyl esters Chemical class 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA00752806A ZA752806B (en) | 1975-04-30 | 1975-04-30 | Novel 11-oxa-prostaglandin analogues derivatives thereof and methods for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH622020A5 true CH622020A5 (en, 2012) | 1981-03-13 |
Family
ID=25568947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH545676A CH623578A5 (en, 2012) | 1975-04-30 | 1976-04-30 | |
| CH153980A CH622020A5 (en, 2012) | 1975-04-30 | 1980-02-26 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH545676A CH623578A5 (en, 2012) | 1975-04-30 | 1976-04-30 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4133817A (en, 2012) |
| JP (1) | JPS51133264A (en, 2012) |
| AU (1) | AU501804B2 (en, 2012) |
| CA (1) | CA1084059A (en, 2012) |
| CH (2) | CH623578A5 (en, 2012) |
| DE (1) | DE2618861A1 (en, 2012) |
| GB (1) | GB1540443A (en, 2012) |
| ZA (1) | ZA752806B (en, 2012) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| US5814660A (en) * | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
| US5866602A (en) * | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
| ATE273009T1 (de) * | 1995-12-22 | 2004-08-15 | Alcon Lab Inc | Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel |
| WO2000020386A1 (en) * | 1998-10-05 | 2000-04-13 | Alcon Laboratories, Inc. | Stannane synthesis of prostanoids |
| US6441196B2 (en) | 2000-05-19 | 2002-08-27 | Alcon, Inc. | Processes and novel intermediates for 11-oxa prostaglandin synthesis |
-
1975
- 1975-04-30 ZA ZA00752806A patent/ZA752806B/xx unknown
-
1976
- 1976-04-22 AU AU13239/76A patent/AU501804B2/en not_active Expired
- 1976-04-29 CA CA251,454A patent/CA1084059A/en not_active Expired
- 1976-04-29 DE DE19762618861 patent/DE2618861A1/de not_active Ceased
- 1976-04-29 US US05/681,742 patent/US4133817A/en not_active Expired - Lifetime
- 1976-04-30 CH CH545676A patent/CH623578A5/de not_active IP Right Cessation
- 1976-04-30 GB GB17811/76A patent/GB1540443A/en not_active Expired
- 1976-04-30 JP JP51049771A patent/JPS51133264A/ja active Pending
-
1980
- 1980-02-26 CH CH153980A patent/CH622020A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US4133817A (en) | 1979-01-09 |
| CH623578A5 (en, 2012) | 1981-06-15 |
| ZA752806B (en) | 1976-12-29 |
| CA1084059A (en) | 1980-08-19 |
| JPS51133264A (en) | 1976-11-18 |
| GB1540443A (en) | 1979-02-14 |
| AU1323976A (en) | 1977-10-27 |
| DE2618861A1 (de) | 1976-11-11 |
| AU501804B2 (en) | 1979-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0002234B1 (de) | Neue Prostacyclinderivate, ihre Herstellung und Anwendung | |
| DE2223365C3 (de) | Prostansäurederivate, Verfahren zu ihrer Herstellung, solche Derivate enthaltende pharmazeutische und veterinäre Zusammensetzungen sowie Zwischenprodukte zur Herstellung dieser Derivate | |
| DE2840032C2 (de) | Prostaglandin-Analoge, Verfahren zu ihrer Herstellung, sowie diese enthaltende Arzneimittel | |
| DE1801750C3 (de) | Prostaglandin-E-Carbinole und deren Tricarbonsäureester | |
| CH622020A5 (en, 2012) | ||
| DE2322655C2 (de) | Prostaglandin F↓2↓↓α↓-ester, Verfahren zu deren Herstellung und deren Verwendung zur Reinigung von Prostaglandin-F↓2↓↓α↓ | |
| DE2315355A1 (de) | Verfahren zur herstellung von oximen | |
| DE2346706A1 (de) | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung | |
| DE2910474C2 (en, 2012) | ||
| DE2743283A1 (de) | Neue prostacyclin-analoga | |
| DE2945781A1 (de) | Prostacyclinzwischenprodukte und protacyclinanaloge | |
| DE2535343C2 (de) | 2-(6'-Carboxy-n-hexyl)-3-n-hexyl-cyclopentanole und -derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| CH615659A5 (en) | Process for the preparation of novel 11,12-secoprostaglandins | |
| CH639950A5 (de) | Verfahren zur herstellung von neuen 13-thiaprostansaeurederivaten. | |
| DE2640692C3 (de) | Optisch aktive 5- (2-Carboxythiophen5-yl)-16phenoxy- a -tetranor- w tetranor-prostaglandine | |
| DE2440919A1 (de) | Prostaglandinanaloge, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| DE2731459A1 (de) | Cyclohexan-analoge vom prostaglandin-typ, verfahren zu deren herstellung und diese enthaltende zusammensetzungen | |
| DE3325677C2 (en, 2012) | ||
| DE2701455A1 (de) | Neue cyclopentanverbindungen | |
| CH615908A5 (en) | Process for the preparation of prostaglandines F-beta | |
| DE1593644C3 (en, 2012) | ||
| AT293361B (de) | Verfahren zur Herstellung von neuen β-Aminoacrylophenonen und deren Salzen | |
| DE2300367A1 (de) | Alkenyl- und alkinylsubstituierte xanthoncarbonsaeuren | |
| DE3541384A1 (de) | Prostacyclin-analoge | |
| DE2209039A1 (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |